Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Petróleo Brasileiro SA (PBR) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Petróleo Brasileiro SATrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Petróleo Brasileiro SA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Petróleo Brasileiro SA trades at $17.83 (market cap $112.19B). The key difference: Petróleo Brasileiro SA is far larger — about 3.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Petróleo Brasileiro SA pays a 9.42% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYPBR
Market Cap
$29.60B$112.19B
Sector
HealthTechnology
52-Week High
$491.22$22.03
52-Week Low
$205.48$11.54
Enterprise Value
$27.56B$172.61B
Dividend Yield
9.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

Petróleo Brasileiro SA

Petrobras (PBR) trades at $17.76, down 3.11% today, amid bearish technical signals despite strong Q2 2026 results showing record production and earnings growth. The company maintains robust fundamentals with a P/E of 4.53, ROE of 30.77%, and consistent dividend payments, though cash flow turned negative in 2026. Recent news highlights production exceeding forecasts and strategic expansions in deepwater operations.

PBR presents a value opportunity with attractive valuations and high profitability, but faces headwinds from regulatory uncertainty and volatile oil prices. Analyst consensus is bullish (50% Buy ratings), yet technical indicators suggest near-term pressure. Investors should weigh strong fundamentals against geopolitical and operational risks in the energy sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Petróleo Brasileiro SA

Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.

Read more on PBR